Study (HPFS) and the Physicians Health Study (PHS) have collected detailed longitudinal data on 52 multiple exposures and traits for approximately 310,000 study participants over the last 35 53 years. Over 160,000 study participants across the cohorts have donated a DNA sample and to 54 date, 20,691 subjects have been genotyped as part of genome-wide association studies (GWAS) 55 of twelve primary outcomes. However, these studies utilized six different GWAS arrays making it 56 difficult to conduct analyses of secondary phenotypes or share controls across studies. To allow 57 for secondary analyses of these data, we have created three new datasets merged by platform 58 family and performed imputation using a common reference panel, the 1,000 Genomes Phase I 59 release. Here, we describe the methodology behind the data merging and imputation and 60 present imputation quality statistics and association results from two GWAS of secondary 61 phenotypes (body mass index (BMI) and venous thromboembolism (VTE)).
INTRODUCTION

73
Large, well-phenotyped cohort studies have constituted the backbone of epidemiology for 74 several decades. Prospectively collected longitudinal information on exposures and outcomes 75 enables a broad spectrum of analyses and has led to novel insights into disease etiology, such as 6 140 Description of GWAS studies and genotyping 141 Since 2007, twelve separate GWAS have been conducted within these four cohorts (Table 1) .
142
The primary traits are breast cancer [16] , pancreatic cancer [43] , glaucoma [44] , endometrial 143 cancer [17] , colon cancer [19] , glioma [45] , prostate cancer [18] , type 2 diabetes [14] , coronary 144 heart disease [15] , kidney stones, gout and mammographic density [20] . These studies were 145 genotyped on six different arrays ( 
157
SNPs that are missing by design (due to different genotyping platforms) from some studies will 158 be correlated with the primary phenotype for that dataset. This might cause spurious results in 159 any secondary analysis on related traits. Although a missing SNP can be imputed, it will have a 160 higher degree of inaccuracy in imputed compared with genotyped SNPs, potentially creating 161 differential measurement error that could also lead to bias [41, 46, 47] . Therefore, we first looked 162 at the overlap of SNPs between different genotyping arrays and identified three broad platform (Figure 1) . To achieve the largest GWAS 168 datasets as possible without losing SNP information, we created three datasets -HumanHap 169 comprising six GWAS datasets, OmniExpress comprising four GWAS datasets and Affymetrix 6.0 170 comprising two GWAS datasets. In the merging process, we removed any SNPs that were not in 171 all studies for a specific platform or had a missing call rate>5%. We flipped strands where 172 appropriate and removed A/T and C/G SNPs to create the final compiled datasets. To identify any SNPs that created spurious associations, we ran several logistic regression 204 analyses among subjects that were selected as controls in the initial GWAS (i.e. excluding all 205 case subjects). For each regression, we used cohort-specific controls from one original GWAS as 206 cases and the rest of the controls in that dataset as controls. For example, in the OmniExpress 207 dataset, we considered NHS controls from the gout GWAS as "cases" while treating controls 208 from the gout (HPFS), endometrial cancer (NHS), colon cancer (NHS, HPFS and PHS), and 209 mammographic density (NHS) as "controls". We repeated this, treating each cohort-specific 210 "controls set" as "cases" and all other controls as "controls". For each GWAS, we extracted 
228
To validate our merged GWAS datasets, we conducted two proof-of principle GWAS of one 229 quantitative trait (BMI) and one binary trait (VTE). We defined BMI as weight (kg)/height 2 (cm) 230 and obtained it by extracting information on weight from the accompanying questionnaire 231 collected at time of blood draw. If weight information was missing, we extracted it from the 232 questionnaire closest in time to time of blood draw. Height was extracted from the baseline 233 questionnaire. We obtained data on BMI for 20,283 participants. VTE is a spectrum of disease 234 that includes pulmonary embolism (PE) and deep vein thromboembolism (DVT). Physician-235 diagnosed PE has been asked on every biennial NHS questionnaire since 1982, and every NHSII 236 and HPFS questionnaire since cohort inception. In the NHS, DVT without PE is captured when a 237 nurse answers that she has had phlebitis or thrombophlebitis (ICD-9=453.x). In NHS, NHSII and 238 HPFS cohorts through 2010 (we did not have VTE data for PHS), we identified 6,041 individuals 239 who reported VTE. Self-reported PE was verified through medical records review by a trained 240 physician (CK). DVT cases are based on self-report, though a validation study of 100 DVT cases 241 found self-reports to be highly consistent (>96%) with medical record review. In total, we 242 identified 1,364 VTE cases with GWAS data. We treated all non-VTE cases with GWAS data as 243 controls (n=17,628). Since we did not have data on VTE in PHS, we excluded PHS from this 
260
Imputation statistics
261
We imputed a total of 31,326,389 markers (29,890,747 SNPs and 1,435,642 indels) and the 262 majority (69%) of these had a MAF<0.01. The average imputation quality score by minor 263 frequency for each platform family is shown in Figure 2 . The imputation quality was very similar 264 across all three datasets (Suppl Figures 1-3) with 49-51% of markers having an imputation 265 quality score 0.3. When restricting to markers with MAF>0.01 (~10 million), 92-94% of the 266 markers had a quality score 0.3. After filtering markers based on MAF (>0.01) and imputation r- 
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(OmniExpress) to 532 (Affymetrix). Thus, combining the individual GWAS datasets into three 297 main datasets enabled association analysis of hundreds of cases rather than tens, leading to 298 more stable estimates in the regression analysis. Platform-specific QQ-plots (Suppl Figures 5a-c) 299 showed no indication of systematic bias (genomic inflation factor =1.00-1.01). The results from 300 the meta-analysis are shown in Figures 6 and 7 (genomic inflation factor =1.00). We observed a 301 strong association located downstream of the F5 gene (strongest associated SNP: rs2040445,
302
OR=2.17, 95% CI: 1. 79-2.63, p=2.70x10 -15 ). We also observed genome-wide significant 303 associations for the ABO locus (strongest associated SNP: rs2519093, OR=1.36, 95% CI: 1.23-1.49, 
312
Thousands of genetic loci associated with hundreds of complex traits have been identified 313 through GWAS and as sample sizes continue to increase, more loci will be discovered. Although 314 the cost of GWAS has dropped, lack of financial resources is still the limiting factor for 315 generating new data. Most GWAS have been conducted in case-control studies, and this has led 316 to the creation of disease-specific consortia in which power can be maximized. However, there 317 is usually only one disease phenotype available from these cases, and little capacity to follow 318 cases or controls to collect information on additional phenotypes that develop over time.
319
Cohort studies are designed to collect multiple endpoints on individuals, but often suffer from 320 limited power for a specific disease. To maximize the utility of existing cohort data resources, it 321 is important to explore associations with additional traits and outcomes that have been 322 collected for individuals in multiple cohorts. In particular, the accumulation of GWAS data within 323 large cohorts with rich environmental and outcome data creates new opportunities to assess 324 novel hypotheses. In addition, cohort studies provide unique opportunities to prospectively 325 assess biomarker-disease associations, thereby minimizing bias due to reverse causation or 326 treatment effects. However, "borrowing" GWAS data between traits is not straightforward.
327
Known issues that can cause bias include technical artifacts due to different genotyping 328 platforms, differences in imputation accuracy and ascertainment bias. Thus, careful data 329 management, imputation procedures and quality checks are needed. Furthermore, if the 330 secondary trait is rare, there will be low phenotypic variability within each GWAS dataset. For 331 example, we observed fewer than 100 VTE cases within the majority of individual GWAS, 332 compared to more than 400 cases within each combined dataset.
334
Our pipeline for combining and imputing twelve different GWAS datasets can overcome both 335 technical and methodological issues. We chose to create three different datasets defined by 336 platform family (in our case, Illumina HumanHap, Illumina OmniExpress and AffyMetrix) since 337 the SNP overlap across platforms was low on a genome-wide scale (75, 285 SNPs) . An attempt to 338 impute a genome-wide dataset comprising only 75,000 SNPs as starting point would have 339 resulted in decreased imputation accuracy in regions of the genome with sparse genotype data.
340
Moreover, it has been shown that different platforms might call SNPs differently and that SNP-341 specific allele frequencies can differ between platforms (see [41] for further discussion). We 342 conducted multiple case-control GWAS among control subjects within each dataset (i.e. running 343 multiple "null" GWAS) and identified and excluded more than 100 SNPs that showed spurious 344 associations. These results emphasize that although datasets are merged by platform family, 345 problematic SNPs giving rise to spurious associations might still exist and it is important to 346 carefully check for these.
348
To assess the validity of our data, we conducted two proof-of-principle GWAS. The first trait we 349 studied was BMI, and in line with what expected, we observed strong evidence of associations 350 with known BMI loci including FTO and TMEM18 that both reached genome-wide significance 351 (P<5x10 -8 ). In addition, out of 32 known BMI SNPs we observed nominal significance (P<0.05) for 352 19 of them, all in the same direction as expected from previous reports. Of note, our sample size 353 (n=20,823) is less than 10% of the original GWAS that had a total sample size of 249,766 354 individuals. Therefore, we would not expect to observe significant associations for all BMI SNPs 355 due to limited power. For VTE, we observed genome-wide significant associations for the F5 and
356
ABO loci that are both known to be associated with VTE. In addition, we also observed a nominal 357 association (P=0.007) with the F11 region. Our BMI and VTE results confirm that GWAS analysis 358 18 of secondary traits in this data is valid and provides a platform for future studies of secondary 359 traits. We ran the BMI and VTE analyses twice, the first time without removing duplicates 360 between the datasets (total of 444 pairs), and the second time with the duplicates removed.
361
Although the 444 pairs constitute less than 5% of our total sample size, including them had an 362 impact on the genomic inflation factor (for BMI, the genomic inflation factor went from 1.09 to 363 1.05 and for VTE, the genomic inflation factor went from 1.02 to 1.00). These results are 364 especially interesting as it is often difficult to identify duplicates across studies when raw data 365 from all participating studies are not available. Care should be taken to remove overlapping 366 subjects across GWAS contributing to a meta-analysis, but any remaining cryptic overlap may 367 inflate association statistics. In that case, statistical adjustment procedures like LD score 368 regression [54] can be used to account for cryptic overlap.
370
One of the main benefits with collecting comprehensive genetic information on cohort subjects 371 is the opportunity to assess interactions between genetic factors and prospectively collected 372 environmental data. To date, few gene-environment interactions have been identified and 373 although their extent and clinical impact remain an open empirical question, the current lack of 374 homogenous large datasets with both genetic and environmental data has precluded 375 comprehensive investigation. Capitalizing on this GWAS resource, we will be able to explore 376 gene-environment interactions for a plethora of outcomes including complex traits such as 377 height and BMI, but also disease outcomes. It will also allow us to study the impact of 378 environmental factors within genetic strata to identify individuals for whom a particular 379 intervention might be especially important [55] [56] [57] [58] .
381
Accumulation of these GWAS data is ongoing and we expect to generate new GWAS data for an 382 19 additional 15,000 participants within the next two years, almost doubling our total GWAS 383 sample size. This growing resource will be a core component of future studies aiming to 384 elucidate how genes and the environment impact public health. 
